Bibliography
The Research
Behind the Protocol
Every phase of the FOXP3 Protocol™ is grounded in peer-reviewed, published science — from the foundational discoveries honored by the 2025 Nobel Prize to the metabolic research shaping each phase.
About this bibliography: This page highlights the core foundational studies — organized by topic, with direct links to PubMed or the original source — that the protocol’s science is built on.
Foundational Discovery — FOXP3, Tregs & the 2025 Nobel Prize
The studies that established regulatory T cells (Tregs) and the FOXP3 gene as the master regulators of immune self-tolerance — the body of work honored by the 2025 Nobel Prize in Physiology or Medicine.
1
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151–1164.
The founding paper of the field — Sakaguchi’s original identification of CD25+CD4+ regulatory T cells as a distinct population that prevents autoimmune disease, directly cited by the Nobel Committee.
View via DOI ↗
2
Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001;27(1):68–73.
The discovery paper that identified the FOXP3 gene itself — co-authored by 2025 Nobel Laureate Fred Ramsdell and Mary E. Brunkow.
PubMed: 11138001 ↗
3
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27(1):20–21.
Established that FOXP3 mutations in humans cause IPEX syndrome — proving the gene’s role in human immune tolerance, not just in mice.
PubMed: 11137993 ↗
4
X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001;27(1):18–20.
Companion paper confirming the human IPEX syndrome as the direct equivalent of the mouse “scurfy” FOXP3 mutation.
PubMed: 11137992 ↗
5
Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057–1061.
The paper that connected the two discoveries — proving FOXP3 directly governs the development and function of regulatory T cells, cementing the framework of peripheral immune tolerance.
Search on PubMed ↗
6
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4(4):330–336.
Independent confirmation that FOXP3 is the master transcriptional “program” for regulatory T cell identity and suppressive function.
Search on PubMed ↗
Metabolism & Immune Regulation — The Phase 2 Science
Research showing that metabolic state — not just genetics — directly determines whether the immune system produces regulatory (Treg) or inflammatory (effector) T cells. This is the mechanistic basis for Phase 2 of the protocol.
7
The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity. 2009.
Landmark study proving that metabolic state directly determines immune cell identity. Low mTOR = Tregs. High mTOR = effector T cells. The metabolic rationale for caloric restriction in Phase 2.
PubMed: 19538929 ↗
8
Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol. 2011.
Proved that Tregs and effector T cells use completely different fuel sources. A fat-burning (ketotic) metabolic environment specifically favors Treg development over effector cell production.
PubMed: 21317389 ↗
9
Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression. Cell Stem Cell. 2014.
Caloric restriction doesn’t just optimize existing immune cells — it triggers generation of new immune cells from stem cells, including regulatory T cells. Phase 2 literally rebuilds the immune system.
PubMed: 24905167 ↗
10
A diet mimicking fasting promotes regeneration and reduces autoimmunity and multiple sclerosis symptoms. Cell Rep. 2016.
A diet structurally similar to Phase 2 produced reduced inflammatory markers, improved clinical symptoms, and immune regeneration in MS patients — direct clinical validation in human autoimmune disease.
PubMed: 27239035 ↗
11
The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015.
Beta-hydroxybutyrate (BHB), the primary ketone body produced in Phase 2, directly blocks the NLRP3 inflammasome — a major driver of inflammatory disease — through a mechanism separate from caloric restriction.
PubMed: 25686106 ↗
12
Nutritional geometry and the redox-inflammatory basis of dietary carbohydrate restriction. Cell Metab. 2021.
Comparing dietary interventions to pharmaceutical interventions: drugs largely dampened responses to diet rather than reshaped them. Food fundamentally alters protein production; drugs suppress responses to food.
PubMed: 34767745 ↗
Official 2025 Nobel Prize Resources
Primary source materials from the Nobel Committee itself, for readers who want to go directly to the original announcement.
13
The 2025 Nobel Prize in Physiology or Medicine — awarded jointly to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their discoveries concerning peripheral immune tolerance.
Official press release and popular science summary of the discovery.
nobelprize.org ↗